Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Earnings

Equities

News

Health Care

Movers

Trading Ideas

General

JAZZ

ZYME

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.

Cancer-Focused Zymeworks&#39; Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251


Zymeworks (NYSE:ZYME) came into focus in late December when major shareholder EcoR1 Capital increased its stake. Already a 10% holder and board member, EcoR1 made several purchases in December and the first days of

Zymeworks in Focus for Insider Activity: Catalysts Ahead

Zymeworks Inc

Press Releases

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Management

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Financing

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

CareDx

Chimerix

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Geron

Gyre Therapeutics

Immunome

LENZ Therapeutics

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Organogenesis Holdings

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Replimune Group

Sionna Therapeutics

ARS Pharmaceuticals

Xencor

Wells Fargo

JP Morgan

HC Wainwright & Co.

Leerink Partners

Citigroup

Zymeworks BC

Comments

Zymeworks

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga